Fondren Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Fondren Management’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-35,000	Closed	-$404K	–	101
2019 Q3	$404K	Buy	+35,000	New	+$368K	0.34%	65

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Fondren Management's AMAG Position: Q4 2019 in Review

Fondren Management sold out of AMAG Pharmaceuticals (AMAG) in Q4 2019, closing a stake of 35,000 shares — an estimated $404K sold.

Fondren Management first reported a position in AMAG in Q3 2019 and held it in 1 quarter. The position peaked at $404K in Q3 2019. 134 funds tracked by Wall St. Rank hold AMAG as of Q4 2019.

Fondren Management reported no remaining AMAG Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Fondren Management sold 35,000 AMAG Pharmaceuticals shares in Q4 2019, an estimated $404K.
Fondren Management first reported a position in AMAG Pharmaceuticals in Q3 2019 and held it in 1 quarter.
Fondren Management's AMAG Pharmaceuticals position peaked at $404K in Q3 2019.
134 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2019.

Based on Fondren Management's 13F filing for Q4 2019, filed 14 Feb 2020.